Alkermes Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 10/11/2026)
| Balance Sheet | Total Assets | 2,486,993,000.00 | ROE | 73.15 % |
| Balance Sheet | Total Equity | 1,819,295,000.00 | ROA | 9.72 % |
| Cashflow | Capital Expenditures | -40,420,000.00 | P/FCF | 13.73 |
| Cashflow | Free Cash Flow | 480,334,000.00 | – | – |
| Cashflow | Operating Cash Flow | 520,754,000.00 | P/CF | 12.66 |
| Income | Earnings per Share (diluted) | 1.43 | Div. Yield | – |
| Income | Net Income | 241,664,000.00 | P/E | 27.33 |
| Income | Shares Outstanding | 168,743,000.00 | P/B | 3.62 |
| Income | Total Revenue | 1,475,900,000.00 | P/S | 4.47 |
Ratios calculated on: 10/14/2026
Company Description
Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of approximately 20 products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis. Its products include ARISTADA, VIVITROL, RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION & INVEGA TRINZA, AMPYRA/FAMPYRA, BYDUREON, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, Aripiprazole Lauroxil Two-Month Dose, ALKS 7119 and RDB 1450. Its product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release technology.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.alkermes.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more